Τίτλος:
Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
MicroRNA-20b-5p (miR-20b-5p) is part of the miR-106a/363 cluster and a member of the cancer-related miR-17 family. miR-20b-5p regulates important transcription factors, including hypoxia-inducible factor 1 (HIF1) and signal transducer and activator of transcription 3 (STAT3). Recently, the dysregulation of miR-20b-5p expression has been observed in many B-cell lymphomas and T-cell leukemias. In this research study, we examined the putative prognostic value of miR-20b-5p in CLL. Therefore, total RNA was isolated from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients; next, total RNA was polyadenylated and first-strand cDNA was synthesized, using an oligo-dT–adapter primer. miR-20b-5p expression was quantified using an in-house–developed real-time quantitative PCR assay. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-20b-5p expression predicts better OS for CLL patients (p < 0.001). Interestingly, miR-20b-5p overexpression retains its favorable prognostic role in CLL patients of intermediate risk or stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable (IGHV) region]. In conclusion, miR-20b-5p is a potential independent molecular biomarker of favorable prognosis in CLL. © 2018
Συγγραφείς:
Papageorgiou, S.G.
Kontos, C.K.
Tsiakanikas, P.
Stavroulaki, G.
Bouchla, A.
Vasilatou, D.
Bazani, E.
Lazarakou, A.
Scorilas, A.
Pappa, V.
Περιοδικό:
Leukemia Research
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
ADP ribosyl cyclase/cyclic ADP ribose hydrolase 1; biological marker; complementary DNA; immunoglobulin heavy chain; microRNA 20b; microRNA 20b 5p; RNA; unclassified drug; immunoglobulin heavy chain; microRNA; MIRN20b microRNA, human; tumor marker, adult; aged; Article; cancer prognosis; chronic lymphatic leukemia; controlled study; female; gene expression; human; human cell; IGHV gene; intermediate risk patient; Kaplan Meier method; major clinical study; male; mutational analysis; overall survival; peripheral blood mononuclear cell; polyadenylation; prediction; priority journal; promoter region; proportional hazards model; protein expression; quantitative analysis; real time polymerase chain reaction; RNA isolation; synthesis; very elderly; cancer staging; chronic lymphatic leukemia; gene expression regulation; genetics; metabolism; middle aged; mononuclear cell; mortality; mutation; prognosis; tumor cell line, Aged; Biomarkers, Tumor; Cell Line, Tumor; Female; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models
DOI:
10.1016/j.leukres.2018.04.014
